Comparable stake leader
Five Narrow Lane LP
SEC ownership of GT Biopharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000109657.
Disclosed value leader
Five Narrow Lane LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- GTBP on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Five Narrow Lane LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Five Narrow Lane LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000109657
- Issuer location
- San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of GT Biopharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Five Narrow Lane LP
Disclosed value leader
Five Narrow Lane LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 10%
13D/G row: Five Narrow Lane LP
Showing 1-8 of 50 holder rows.
Quick read
Five Narrow Lane LP leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Five Narrow Lane LP's linked filing trail.
Comparable ownership
Top 5
Five Narrow Lane LP
10%
CYTOVANCE BIOLOGICS INC
9.8%
BRISTOL INVESTMENT FUND LTD
2.4%
VANGUARD CAPITAL MANAGEMENT LLC
12%
GEODE CAPITAL MANAGEMENT, LLC
8.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Five Narrow Lane LP |
13D/G
|
10%
|
$552,386
253,388 shares
|
$0 | 13 May 2025 |
| CYTOVANCE BIOLOGICS INC |
13D/G
|
9.8%
|
$478,416
219,457 shares
|
$0 | 30 Sep 2024 |
| BRISTOL INVESTMENT FUND LTD |
13D/G
|
2.4%
|
$171,405
74,524 shares
|
$0 | 29 May 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
12%
|
$184,436
376,399 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
8.5%
|
$130,648
266,788 shares
|
— | 30 Jun 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
7.2%
|
$110,710
225,938 shares
|
— | 30 Jun 2026 |
| HRT FINANCIAL LP |
13F
Company
|
3.4%
|
$52,000
107,140 shares
|
— | 30 Jun 2026 |
| Everhart Financial Group, Inc. |
13F
Company
|
3.2%
|
$48,970
100,000 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 12 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to GT Biopharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Manu Ohri
Net 12M change
$0
Latest report
04 Sep 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Manu Ohri | CFO & Secretary | $100,450 | Mixed | 11 Aug 2023 | ||
| Gregory Berk | Pres. of R&D, CMO | Mixed | 15 Jul 2022 | |||
| Michael Martin Breen | CEO and Director, Director | Mixed | 04 Sep 2025 | |||
| Andrew J. Ritter | Director | Mixed | 08 May 2025 | |||
| Bruce Wendel | Director | Mixed | 27 Jan 2023 | |||
| Rajesh C. Shrotriya MD | Director | Mixed | 27 Jan 2023 | |||
| Gavin Choy | Acting Chief Financial Officer | Mixed | 31 Dec 2021 | |||
| Charles J. Casamento | Director | Mixed | 04 Sep 2025 | |||
| Hilary Kramer | Director | Mixed | 04 Sep 2025 | |||
| Alan Louis Urban | Chief Financial Officer | Mixed | 04 Sep 2025 | |||
| David C. Mun-Gavin | Director | Mixed | 04 Sep 2025 |
Recent insider transactions for GT Biopharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.